Gastrointestinal Stromal Tumor Patients Need Medication After Surgery – Here's Why

Gastrointestinal Stromal Tumor (GIST) is a type of malignant tumor that originates from the mesenchymal tissue of the stomach. It is typically diagnosed through genetic and pathological testing. One of the key characteristics of this tumor is its high sensitivity to a targeted therapy drug called Imatinib.

Despite successful surgical removal, there is still a risk of recurrence or metastasis, as it is difficult to completely eliminate all cancerous cells through surgery alone. This is why post-operative treatment with Imatinib plays a crucial role in managing the disease.

Studies have shown that patients who take medication for three years after surgery have significantly better outcomes than those who do not. For patients with intermediate-risk tumors, doctors often recommend continuing Imatinib for at least two years. In high-risk cases, or when surgery is not an option, long-term treatment may be necessary. Encouragingly, patients who have taken the medication for four to five years have shown excellent disease control, even in cases where surgery was not performed.

This advancement in treatment has changed the way we view GIST. It is no longer seen solely as a life-threatening cancer, but rather as a manageable chronic condition—similar to hypertension or diabetes. With consistent medication, patients can effectively control tumor growth and enjoy a long-term, high-quality life.

Proper follow-up care and adherence to prescribed medication are essential for long-term survival. Patients should work closely with their healthcare providers to monitor their condition and adjust treatment plans as needed.